Teva Pharmaceutical Industries (TEVA+4.3%) is up on modestly higher volume in early trade. Shares have rallied ~13% since last week when the FDA OK'd its generic EpiPen and it announced positive late-stage data on fasinumab.
Teva Continues Rebound, Up 4%
-
Sponsored -
Agency/Corporate ProgramEinhorn Barbarito Frost & Botwinick Elevates Matthew Rheingold to Partner
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn Barbarito Frost & Botwinick Partners Thomas Snyder and Matheu Nunn Named as Co-Chairs of Firm’s Family/Matrimonial Practice
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
McCarter & English’s Mark Anania Named President of the New Jersey Intellectual Property Law Association
Mark H. Anania, a partner at McCarter & English, LLP, has been named President of the New Jersey Intellectual Property Law Association
Anthony Chwastyk Joins Cohen Seglias as Senior Counsel
Cohen Seglias Pallas Greenhall & Furman PC is pleased to announce that Anthony H. Chwastyk has joined the
TRUSTED BY
THESE PARTNERS:
